Equillium (NASDAQ:EQ) Stock

Equillium

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Equillium Inc

Invesco Russell 1000 Equal Weight ETF

EQT AB

Equity Bancshares, Inc. Class A Common Stock

Equity Bancshares Inc

Mensa Mining Corp

Equity Commonwealth Com Sh Ben Int

EQUITABLE FINCL CORP by Equitable Financial Corp.

Equitable Financial Corp

EQB Inc

Equitable Holdings Inc

Equitable Holdings, Inc. Depositary Shares

Equitable Holdings, Inc. Depositary Shares, each representing a 1/1,000th interest in a share of Fixed Rate Noncumulative Perpetual Preferred Stock, Series C

Columbia U.S. Equity Income ETF

EQUINITI GROUP PLC ADR by Equiniti Group PLC

Equinix Inc

ALPS Equal Sector Weight ETF

EQ Labs Inc

Simplify Exchange Traded Funds Simplify Market Neutral Equity Long/Short ETF

iShares Trust iShares MSCI Emerging Markets Quality Factor ETF

EQUITY METALS CORPORATION by Equity Metals Corporation

Equity Metals Corp

Equinor ASA

EQUINOX RES LTD by EQUINOX RES LTD

Eqonex Ltd Ordinary Shares

Equity Residential Common Shares of Beneficial Interest

Equity Residential

ProShares Equities for Rising Rates ETF

EQRX INC COM

EQRX INC WT EXP

Equus Total Return Inc

EQS GROUP AG by EQS GROUP AG

EQT Corp

Equal Trading Inc

EQM Technologies & Energy Inc Com

EQUITECH INTL CORP by Equitech Int'l Corp.

Equitech International Corp

Equitrans Midstream Corp PRF PERPETUAL USD - Ser 4/A2

ALTAMIRE GOLD CORP ORD by Altamira Gold Corp

Altamira Gold Corp

Lake Winn Resources Corp

LAKE WINN RESOURCES CORP by Lake Winn Resources Corp

Valued Advisers Trust Kovitz Core Equity ETF

QuadrantProtocol

EQUATORIAL ENERGIA S/ADR by Equatorial Energia S.A.

Equatorial SA

IndexIQ ETF Trust NYLI Engender Equality ETF

E-Qure Corp

EQV Ventures Acquisition Corp. Class A Ordinary Shares

EQV Ventures Acquisition Corp

EQV Ventures Acquisition Corp. Units, each consisting of one Class A ordinary share and one-third of one redeemable warrant

EQV Ventures Acquisition Corp. Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share

Invesco S&P 100 Equal Weight ETF

Equinox Gold Corp

Equalizer

UBS analyst William Appicelli upgrades Evergy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVRG#NASDAQ">EVRG</a>) from Neutral to Buy and raises the price target from $68 to $78.

News

Upgrades

Price Target

Analyst Ratings

EVRG

UBS Upgrades Evergy to Buy, Raises Price Target to $78

Ascendiant Capital analyst Edward Woo maintains Knightscope (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSCP#NASDAQ">KSCP</a>) with a Buy and lowers the price target from $32 to $30.

KSCP

Ascendiant Capital Maintains Buy on Knightscope, Lowers Price Target to $30

Citigroup analyst Paul Lejuez upgrades On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) from Neutral to Buy and lowers the price target from $65 to $60.

ONON

Citigroup Upgrades On Holding to Buy, Lowers Price Target to $60

WIIM

RVMD

Revolution Medicines shares are trading higher after the company announced new clinical data for zoldonrasib as monotherapy in patients with KRAS G12D mutant non-small cell lung cancer.

RVTY

Revvity shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 sales guidance with its midpoint above estimates.

Barclays analyst Paul Kearney initiates coverage on Columbia Sportswear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLM#NASDAQ">COLM</a>) with a Equal-Weight rating and announces Price Target of $64.

Initiation

COLM

Barclays Initiates Coverage On Columbia Sportswear with Equal-Weight Rating, Announces Price Target of $64

Rithm Property Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPT#NYSE">RPT</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $0.01 by 100 percent. The company reported quarterly sales of $2.49 million which missed the analyst consensus estimate of $4.83 million by 48.44 percent.

Earnings

Earnings Beats

Earnings Misses

Rithm Property Trust Q1 Adj. EPS $0.02 Beats $0.01 Estimate, Sales $2.49M Miss $4.83M Estimate

Ascendiant Capital analyst Edward Woo maintains Banzai International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNZI#NASDAQ">BNZI</a>) with a Buy and lowers the price target from $30 to $26.

BNZI

Ascendiant Capital Maintains Buy on Banzai International, Lowers Price Target to $26

Barclays analyst Paul Kearney initiates coverage on Kohl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) with a Underweight rating and announces Price Target of $4.

Barclays Initiates Coverage On Kohl's with Underweight Rating, Announces Price Target of $4

Barclays analyst Paul Kearney initiates coverage on Carter's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRI#NYSE">CRI</a>) with a Underweight rating and announces Price Target of $25.

Barclays Initiates Coverage On Carter's with Underweight Rating, Announces Price Target of $25

NANO Nuclear Energy Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) ("NANO Nuclear" or "the Company"), a leading advanced nuclear energy and technology company focused on developing clean energy solutions, today announced that on Thursday, April 24, 2025, a Las Vegas judge granted in full two motions to dismiss brought by NANO Nuclear Energy Inc. and its officers and directors in a putative shareholder derivative action entitled Latza v. Walker, et al., Case No. A-24-900423-B, Clark County, Nevada District Court.
"We are extremely pleased that this case has been so promptly adjudicated and dismissed in its entirety," said Jay Yu, Founder and Chairman of NANO Nuclear. "This ruling will allow us to devote more of our time and attention to NANO Nuclear's primary mission of becoming the leading commercially focused advanced nuclear energy technology company in America. We thank our legal team at Ellenoff Grossman &amp; Schole for their insight and hard work in achieving this result."

Legal

Judge Tosses Case Against NANO Nuclear Leaders, Company Refocuses on Advanced Nuclear Tech Growth

Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNXT#NASDAQ">RNXT</a>) with a Buy and raises the price target from $9 to $11.

RNXT

Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $11

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</h3>
<ul>
<li>On April 21, UnitedHealth reported worse-than-expected first-quarter results and cut its FY25 adjusted EPS guidance below estimates. "UnitedHealth Group grew to serve more people more comprehensively but did not perform up to our expectations, and we are aggressively addressing those challenges to position us well for the years ahead, and return to our long-term earnings growth rate target of 13 to 16%," said Andrew Witty, CEO of UnitedHealth. The company's stock fell around 19% over the past month and has a 52-week low of $412.02.</li>
<li>RSI Value: 27.1</li>
<li>UNH Price Action: Shares of UnitedHealth fell 1.3% to close at $418.64 on Friday.</li>
<li>Edge Stock Ratings: 26.37 Momentum score with Value at 69.10. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/UNH"><img loading="lazy" decoding="async" width="481" height="192" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28070358/image-186.png" alt="" class="wp-image-890598" style="width:331px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28070358/image-186.png 481w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28070358/image-186-300x120.png 300w" sizes="(max-width: 481px) 100vw, 481px" /></a></figure>
<h3 class="wp-block-heading">Bristol-Myers Squibb Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)&nbsp;&nbsp;</h3>
<ul>
<li>On April 24, Bristol Myers Squibb reported first-quarter 2025 revenues of $11.20 billion, beating the consensus of $10.70 billion. &#8220;Our strong execution in the first quarter drove continued momentum across our Growth Portfolio and meaningful progress in the pipeline,&#8221; said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb. The company's stock fell around 20% over the past month and<a href="https://www.benzinga.com/quote/BMY"> has a 52-week low</a> of $39.35.</li>
<li>RSI Value: 25</li>
<li>BMY Price Action: Shares of Bristol-Myers Squibb dipped 1.6% to close at $47.90 on Friday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0428">BMY stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0428"><img loading="lazy" decoding="async" width="916" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28071255/image-187.png" alt="" class="wp-image-890615" style="width:544px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28071255/image-187.png 916w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28071255/image-187-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28071255/image-187-768x710.png 768w" sizes="(max-width: 916px) 100vw, 916px" /></a></figure>
<h3 class="wp-block-heading">X4 Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XFOR#NASDAQ">XFOR</a>)</h3>
<ul>
<li>On April 24, X4 Pharmaceuticals company announced a 1-for-30 reverse stock split. The company has a 52-week <a href="https://www.benzinga.com/quote/XFOR">low of $0.17.</a></li>
<li>RSI Value: 14.7</li>
<li>XFOR Price Action: Shares of X4 Pharmaceuticals closed at $5.70 on Friday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0428">XFOR shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0428"><img loading="lazy" decoding="async" width="876" height="841" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28071347/image-188.png" alt="" class="wp-image-890619" style="width:566px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28071347/image-188.png 876w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28071347/image-188-300x288.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28071347/image-188-768x737.png 768w" sizes="(max-width: 876px) 100vw, 876px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a> 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/45007044/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-delivering-high-dividend-yields-5">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

XFOR

Top 3 Health Care Stocks That May Rocket Higher In April

In connection with its name change, the Company also plans to change its ticker symbol for the Barrick common shares listed on the New York Stock Exchange from ‘GOLD' to ‘B', to become effective at the start of trading on May 9, 2025. The Barrick common shares will continue to trade under the ‘ABX' ticker symbol on the Toronto Stock Exchange. The new CUSIP number for the Barrick common shares effective at the start of trading on May 9, 2025 will be 06849F108.

GOLD

Barrick Gold Plans To Rebrand As Barrick Mining Corporation And Change NYSE Ticker To 'B'

Barclays analyst Paul Kearney initiates coverage on Macy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) with a Equal-Weight rating and announces Price Target of $12.

Barclays Initiates Coverage On Macy's with Equal-Weight Rating, Announces Price Target of $12

Needham analyst James Ricchiuti maintains Bel Fuse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BELFB#NASDAQ">BELFB</a>) with a Buy and lowers the price target from $100 to $95.

BELFB

Needham Maintains Buy on Bel Fuse, Lowers Price Target to $95

Acquisition Supports Company's Growth in Innovative Lifestyle Offerings
BETHESDA, Md., April 28, 2025 /PRNewswire/ -- Today, Marriott International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) announced it has reached an agreement to acquire the lifestyle brand <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4414142-1&amp;h=2489686303&amp;u=https%3A%2F%2Fwww.citizenm.com%2F&amp;a=citizenM">citizenM</a>, a unique and innovative offering in the select-service segment. The transaction is expected to accelerate Marriott's global expansion of its select-service and lifestyle lodging offerings, as the company continues to focus on expanding its portfolio to provide even more exciting options for guests and Marriott Bonvoy members around the world.
At closing of the transaction, Marriott will pay $355 million to acquire the brand and related intellectual property. Following closing, the citizenM portfolio will become part of Marriott's system, with the hotels owned and leased by the seller subject to new long-term franchise agreements with Marriott. Stabilized fees for the open and under construction pipeline portfolio are anticipated to be approximately $30 million annually. The seller may also receive earn-out payments up to $110 million that are based on the future growth of the brand over a specified, multi-year timeframe. These payments would not begin until the fourth year following closing.
 &nbsp;

Marriott International Agrees To Acquire citizenM And Its Intellectual Property In $355M Deal

Barclays analyst Paul Kearney initiates coverage on Gildan Activewear (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIL#NYSE">GIL</a>) with a Overweight rating and announces Price Target of $51.

Barclays Initiates Coverage On Gildan Activewear with Overweight Rating, Announces Price Target of $51

CSTL

Castle Biosciences Surpasses 200,000 DecisionDx-Melanoma Clinical Test Orders

The ongoing dispute in Louisiana over who should bear the cost of new power plants required for&nbsp;Meta Platforms Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) $10 billion data center is heating up.
What Happened: The Louisiana Public Service Commission received new testimony on April 11 from consumer advocates and climate groups. They urged the state regulator to reject a proposal by Meta&#8217;s electricity provider, Entergy Louisiana, to pass on $5 billion in construction costs for the plants to its entire customer base, <a href="https://www.businessinsider.com/meta-data-center-louisiana-5b-ratepayers-2025-4">reported</a> Business Insider on Saturday.
Entergy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>) has put forward a proposal to construct three new natural gas power plants to support Meta&#8217;s data centers. The utility contends that the data center could have a significant impact on the state, potentially creating 300 to 500 jobs with an average salary of $82,000.
However, advocates and climate groups argued that Entergy&#8217;s 1.1 million electric customers should not bear the cost of Meta&#8217;s power usage. Cathy Kunkel, an energy consultant, also cautioned that the utility&#8217;s plan could &#8220;put other ratepayers at risk of having to absorb hundreds of millions, if not billions of dollars, of additional costs&#8221; tied to Meta&#8217;s data center.
Even Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) in Louisiana has raised concerns, seeking a guarantee that Meta&#8217;s increasing power demand will not affect it or other Entergy customers in the state.
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/04/45003759/arks-bitcoin-bear-case-is-300000-by-2030-whats-the-bull-case" target="_blank" rel="noreferrer noopener">ARK&#8217;s Bitcoin &#8216;Bear Case&#8217; Is $300,000 By 2030—What&#8217;s The Bull Case? &#8211; Benzinga</a>
Why It Matters: &nbsp;The controversy surrounding the funding of Meta&#8217;s data center highlights the broader issue of who should bear the cost of tech companies&#8217; increasing power consumption. As these companies continue to expand their data centers, the demand for electricity is likely to rise, potentially leading to higher costs for consumers.&nbsp;
These concerns stem from the fact that Meta&#8217;s power requirements have grown since the company <a href="https://www.benzinga.com/24/12/42337936/meta-unveils-10-billion-ai-data-center-in-louisiana-a-game-changer-for-tech-and-jobs">first revealed </a>its intention to construct an AI data center in Louisiana, which has contributed to higher service costs for Entergy. The precise amount of additional electricity Meta is requesting remains unclear, as the relevant details have been redacted from the filings.
This situation is further complicated by the reports of recent pullout of Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) from data center leases, raising questions about the sustainability of the AI development boom.&nbsp;However, Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Amazon have recently <a href="https://www.benzinga.com/25/04/45001873/amazon-and-nvidia-dismiss-fears-of-ai-data-center-pullback-we-continue-to-see-very-strong-demand">denied reports</a> of slowdown in AI data center construction. 
The momentum rating of META is 75.93% while its growth rating is 75%, according to&nbsp;<a href="https://www.benzinga.com/quote/META" target="_blank" rel="noreferrer noopener">Benzinga&#8217;s Proprietary Edge Rankings</a>. For an in-depth report on more stocks and insights into growth opportunities,&nbsp;<a href="https://www.benzinga.com/screener/top-momentum-stocks" target="_blank" rel="noreferrer noopener">sign</a>&nbsp;<a href="https://www.benzinga.com/screener/top-momentum-stocks" target="_blank" rel="noreferrer noopener">up for Benzinga Edge.</a>
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/25/04/45031932/donald-trump-says-democrats-did-everything-possible-to-destroy-christopher-columbus-vows-to-restore-his-statues-and-reputation" target="_blank" rel="noreferrer noopener">Trump Vows To Bring Back Columbus Day &#8216;From The Ashes,&#8217; Promises To Restore &#8216;Same Rules, Dates And Locations&#8217; &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Tech

AMZN

MSFT

NVDA

Meta's Louisiana Data Center Sparks Debate Over Who Should Foot The $5 Billion Power Bill: '...Put Other Ratepayers At Risk Of Having To Absorb Hundreds Of Millions,' Says Expert

Comments

Equillium

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL